Analysis
StimCardio Medical has closed an oversubscribed $30 million Series A financing, led by Metis MedTech, to advance Rhyvive, its investigational wrist-worn neuromodulation therapy for atrial fibrillation, according to Pulse2. The round adds to the funding activity Value Add Pulse tracks across medtech and digital health deals. The round funds a planned multicenter pivotal study and preparation for a De Novo submission to the U.S. Food and Drug Administration.
What StimCardio Medical does
Rhyvive is designed as an adjunctive therapy for patients who undergo catheter ablation, the standard procedural treatment for atrial fibrillation. The device combines physiological sensing with personalized, non-invasive median nerve stimulation in a closed-loop system, aiming to extend AFib treatment beyond the procedure room and into the patient's home. The company has not disclosed a founding year or headquarters in its own materials; an SEC Form D filing lists StimCardio Medical's registered address at 1925 Century Park E, Suite 1700, in Los Angeles. Amir Soltanianzadeh serves as chief executive.
StimCardio Medical funding history
The company's clinical groundwork predates this round: a randomized, double-blind, sham-controlled pilot study called NeuroPulse 1 was presented as a late-breaking trial at HRX Live 2026 and published in Heart Rhythm, showing a statistically significant reduction in recurrent atrial arrhythmia events versus sham. This $30 million Series A, described by the company as oversubscribed, will fund NeuroPulse 2, a larger pivotal study testing whether adding wearable neuromodulation to ablation improves outcomes versus ablation alone. No prior equity round amount has been disclosed.
“Rhyvive is designed as an adjunctive therapy for patients who undergo catheter ablation, the standard procedural treatment for atrial fibrillation.”
Who invested in StimCardio Medical
Metis MedTech, John Slump's family office, led the Series A. Slump also sits on StimCardio's board. Catalyst Health Ventures, led by managing partner Joshua Phillips, participated alongside unnamed strategic corporate investors. "Our decision to invest reflects our strong conviction in this impressive team, disruptive technology, and growing market," Slump said. Phillips added that the technology, "supported by encouraging early clinical evidence," has the potential to reduce AFib recurrence.
AFib device market and competitors
The global wearable atrial fibrillation detection devices market was valued at $596.2 million in 2024 and is projected to grow at a 17.4% compound annual rate from 2025 to 2034, according to Global Market Insights, which names AliveCor, Apple, Garmin, Samsung, Withings and iRhythm among the players in that space. Those companies largely sell detection products -- watches and patches that flag an AFib episode -- rather than StimCardio's therapeutic neuromodulation approach, so the comparison is more about adjacent market size than direct competition. StimCardio's own framing is that roughly 59 million people worldwide live with AFib, and that 30% to 40% of ablation patients see the condition recur, which is the population Rhyvive is built to serve if it clears the FDA.
What to watch next
The near-term milestones are enrollment in the NeuroPulse 2 pivotal study and the timing of a De Novo submission -- a regulatory pathway for novel, lower-risk devices that is typically faster than a full PMA but still requires clinical evidence most wearable-detection products never needed. Until that submission clears, Rhyvive remains an investigational device, and the $30 million round is a bet on trial results that have not yet been generated, not on commercial revenue.